Background: Blood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with neoadjuvant chemotherapy and immunotherapy.
Objective: The objective of this study was to compare the prognostic value of existing commonly used blood inflammatory index in patients with advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy.
Methods: The clinicopathological data of patients with advanced gastric cancer from three centers in China were analyzed retrospectively. Univariate COX regression analysis was used to analyze the independent risk factors of poor tumor regression and overall survival (OS) in this part of patients, and the predictive value of different inflammatory indexes on prognosis was compared by C-index index. Finally, Inflammatory burden index(IBI) was grouped by X-tile software, and Kaplan-Meier method was used to compare the survival difference between groups.
Results: A total of 163 patients were enrolled in this study. The median age was 63 years(56-68). The median cycle of neoadjuvant therapy was 4(3-4). The median survival time was 85.1%(1 years), 65.6%(2 years), and 47.4%(3 years).Univariate analysis showed that IBI was an independent risk factor for non-TR(residual tumor cells>50%) (HR=1.08,95%CI:1.00-1.45,p<0.001)and OS(HR=1.04,95%CI:1.03-1.05,p<0.001). IBI is the best predictor of OS (C-index: 0.82, 95% CI: 0.78-0.87) among all inflammatory indexes. The IBI cutoff value was 52.1. It was found that the high IBI group had a higher incidence of postoperative complications(32.1%vs14.3%, p=0.001), the proportion of non-TR patients was significantly higher than that of the low IBI group(64.3%vs35.7%, p =0.001), and the high IBI group had a significantly lower OS((47.6% vs 87.6%, p < 0.001).
Conclusion: IBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients' treatment decisions. This result still needs to be verified by large prospective studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790653 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1471399 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential New Tumors Associated with Hereditary Breast and Ovarian Cancer (HBOC).
Keio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFEffect of Perioperative Immunonutrition on Outcomes in Gastric Cancer Surgery Patients: A Systematic Review and Evidence Map.
Clin Nutr ESPEN
March 2025
Xuanwu Hospital, Capital Medical University, Beijing, China; School of Nursing, Capital Medical University, Beijing, China. Electronic address:
Background: Tumors and surgical procedures trigger a series of metabolic responses that put gastric cancer patients at constant risk of malnutrition during the perioperative period. Meanwhile, the effectiveness of enteral immunonutrition (EIN) for these patients remains a subject of ongoing debate.
Objective: This systematic review and evidence map aim to retrieve randomized controlled trials (RCTs) on perioperative EIN interventions in gastric cancer patients undergoing surgery and evaluate their effectiveness.
Letter to Editor regarding: rethinking hospital status in gastric cancer surgery.
J Gastrointest Surg
March 2025
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, China. Electronic address:
[A Case of Pancreatic Carcinoma and Short Bowel Syndrome with Long-Term Survival].
Gan To Kagaku Ryoho
February 2025
Dept. of Surgery, Kinan Hospital.
A 75-year-old woman was admitted to our hospital with a complaint of jaundice and elevated liver enzyme levels. She was diagnosed with pancreatic head carcinoma after examination. She had undergone massive resection of the small intestine due to thrombosis of the superior mesenteric artery at 48 years of age, and the remaining ileum was approximately 70 cm in length.
View Article and Find Full Text PDF[Robotic Gastrectomy Contributed to Safe Surgery in a Patient with Gastric Cancer with Severe Pulmonary Dysfunction Due to Myasthenia Gravis].
Gan To Kagaku Ryoho
February 2025
Dept. of Digestive Surgery, Kyoto First Red Cross Hospital.
Robotic gastrectomy is a safe and minimally invasive approach that may reduce the risk of complications in patients with severely impaired pulmonary function. Here, we report the successful treatment of an 80-year-old patient with gastric cancer and myasthenia gravis(MG)using perioperative respiratory rehabilitation and robotic gastrectomy with D2 lymphadenectomy. Patients with gastric cancer and severe pulmonary dysfunction are at a risk of postoperative respiratory disorders, including severe pneumonia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!